- Home
- / Ulisse BioMed
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Ulisse BioMed financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€0.9
2024-10-29
Market Capitalization
€20.7 M
2024-10-29
Revenue
€768 K
FY, 2024
CreditSafe Score
?
Score changed on Jul 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|
| Revenue | 428.0K | 277.0K | 138.0K | 261.0K | 768.0K |
| Cost of goods sold | 299.0K | 547.0K | 1.0M | 1.6M | 1.8M |
| Gross profit | 391.0K | (135.0K) | (501.0K) | (1.4M) | (597.0K) |
| Gross profit margin, % | 91.4% | -48.7% | -363.0% | -518.4% | -77.7% |
| Operating expense total | 118.0K | 222.0K | 487.0K | 788.0K | 2.4M |
| Depreciation and amortization | 49.0K | 248.0K | 319.0K | 2.7M | 2.9M |
| EBITDA | 273.0K | (357.0K) | (988.0K) | (2.1M) | (3.0M) |
| EBITDA margin, % | 63.8% | -128.9% | -715.9% | -820.3% | -389.1% |
| EBIT | 224.0K | (605.0K) | (1.3M) | (4.8M) | (5.9M) |
| EBIT margin, % | 52.3% | -218.4% | -947.1% | -1837.5% | -769.7% |
| Interest expense | 24.0K | ||||
| Pre tax profit | 224.0K | (604.0K) | (1.3M) | (4.8M) | (5.9M) |
| Income tax expense | 3.0K | ||||
| Net Income | 221.0K | (604.0K) | (1.3M) | (4.8M) | (5.9M) |